• The new ABC of HIV Prevention By Gita Ramjee
• Choosing the nucleoside backbone : Efficacy and safety of nucleosides and
  non-nucleoside in first line regimens By Andrew Hill
• Commencing ART in patients with advanced HIV disease By Robert Murphy
• Are children different to adults? First line regimens in the paediatric clinic
  By Diana Gibb
• Is it smart to interrupt therapy? By Jintanat Ananworanich
• Is it just a dream? By Victor Valcour
  
  Lunch Symposium
• 
  
  Workshops
  
  - Neuro AIDS workshop
• 
  - Masking sense of anti-retroviral testing
• 
  
  
  

  ---

  
  

• Immune Failure in HIV Infection and Immune Recover on HAART By Sharon Lewin
• Constructing a regimen in patients with failure of first line therapy
  By Kiat Ruxrungtham
• The goals of salvage therapy in highly treatment experienced patients
  By Jonathan Shapiro
• Chronic Viral Hepatitis : If we have the drug , can it be cured? By Greg Dore
• Cervical dysplasia and carcinoma : The new anti cancer vaccine By Graham Leggatt
• PMCT….Heavy, light or medium By Thanyawee Puthanakit
  
  Lunch Symposium
• DARUNAVIR in Treatment-experienced Patients
• Management of Treatment experienced Patients
  
  Workshops
  
  - Opportunistic infection and STD workshop
• 
  - Paediatric workshop
• Part I_Topic I-III
• Part II_Topic_IV_V
  - Pharmacokinetic and Therapeutic Drug Monitoring Workshop
• 
  
  
  

  ---

  
  

• The Evolution of HIV By Francine McCutcham
• Nevirapine pharmacokinetics in clinical practice : Everything you always wanted to know
  By David Burger
• HIV and cardiovascular risk By Peter Reiss
• To circumcise or not? By Bernard Hirschel
• Using protease inhibitors in resource limited settings By Mark Boyd
• Positive prevention among positive people : What are the issues?
  By John Kaldor
  
  Lunch Symposium
• 
  
  
  

  ---